We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Genelux Corp (GNLX) USD0.001

Sell:$3.84 Buy:$3.89 Change: $0.22 (5.89%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$3.84
Buy:$3.89
Change: $0.22 (5.89%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$3.84
Buy:$3.89
Change: $0.22 (5.89%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Genelux Corporation is a late clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patient’s tumor neoantigens. Its product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. Olvi-Vec is developed for the treatment of multiple cancers based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. Its portfolio also include oncolytic vaccinia immunotherapy clinical candidates.

Contact details

Address:
2625 Townsgate Road, Suite 230
WESTLAKE VILLAGE
91361
United States
Telephone:
+1 (805) 2679889
Website:
https://genelux.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
GNLX
ISIN:
US36870H1032
Market cap:
$98.54 million
Shares in issue:
27.00 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Thomas Zindrick
    Chairman of the Board, President, Chief Executive Officer
  • Lourie Zak
    Chief Financial Officer
  • Joseph Cappello
    Vice President of Pharmaceutical Development, General Manager of Manufacturing
  • Tony Yu
    Vice President - Clinical Trial Operations
  • Sean Ryder
    General Counsel, Corporate Secretary
  • Caroline Jewett
    Head of Quality
  • Paul Scigalla
    Chief Medical Officer
  • Ralph Smalling
    Head of Regulatory

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.